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968 PERKIN ET ALBackground: Food allergy is thought to develop through
transcutaneous sensitization, especially in the presence of skin
barrier impairment and inflammation. Regular moisturizer
application to infant skin could potentially promote
transcutaneous sensitization and the development of food allergy.
Objectives: We tested this hypothesis in the Enquiring About
Tolerance (EAT) study population.
Methods: The EAT study was a population-based randomized
clinical trial conducted from January 15, 2008, to August 31,
2015, and recruited 1303 exclusively breastfed 3-month-old
infants and their families from England and Wales. At
enrollment at 3 months, families completed a questionnaire that
included questions about frequency and type of moisturizer
applied, use of corticosteroid creams, and parental report of dry
skin or eczema. Infants were examined for visible eczema at the
enrollment visit.
Results: A statistically significant dose-response relationship
was observed between parent-reported moisturization
frequency at 3 months of age and the subsequent development
of food allergy. Each additional moisturization per week was
associated with an adjusted odds ratio of 1.20 (95% CI, 1.13-
1.27; P < .0005) for developing food allergy. For infants with no
visible eczema at the enrollment visit, the corresponding
adjusted odds ratio was 1.18 (95% CI, 1.07-1.30; P 5 .001) and
for those with eczema at the enrollment visit, 1.20 (95% CI,
1.11-1.31; P < .0005). Moisturizer frequency showed similar
dose-response relationships with the development of both food
and aeroallergen sensitization at 36 months.
Conclusions: These findings support the notion that regular
application of moisturizers to the skin of young infants may
promote the development of food allergy through
transcutaneous sensitization. (J Allergy Clin Immunol
2021;147:967-76.)
Key words: Moisturization, food allergy, allergy prevention,
children, eczema, skin barrier, TEWL, filaggrin
Murine data have demonstrated that food sensitization can
occur via transcutaneous food allergen exposure, enhanced by an
impaired skin barrier,1-3 and a recent review of human data
concluded that an increasing body of evidence supported the
role of a disrupted, inflamed skin barrier as the root cause for
the development of food sensitization and allergy.4 The apprecia-
tion that oral consumption of food allergen could induce oral
tolerance led to Gideon Lack proposing the dual allergen hypoth-
esis: that in humans, sensitization to food allergen occurs through
environmental exposure to allergen through the skin and that oral
consumption of food allergen induces immune tolerance.5 Lack
proposed 3 novel interventional strategies to prevent the develop-
ment of food allergies. The first was that prompt intensive treat-
ment of eczema in early infancy would decrease inflammation
in the skin, reduce skin permeability, and prevent allergic sensiti-
zation to foods. Evidence to support this has recently emerged in
Japan in a retrospective cohort study where early aggressive treat-
ment of eczema in infants with atopic dermatitis (AD) was asso-
ciated with a significant decrease in later development of food
allergies.6 A randomized trial to validate this finding, the Preven-
tion of Allergy via Cutaneous Intervention (PACI) study is under-
way (UMIN000028043).7 The second was that a reduction of
food allergens in the child’s environment would lead to areduction in sensitization. The third was that the early introduc-
tion of allergenic foods to the infant’s diet (in the first 6 months
of life) could reduce the development of food allergies through
oral tolerance induction. A number of randomized controlled tri-
als have been undertaken and a systematic review of these has
confirmed efficacy of early introduction of peanut and egg in pre-
venting allergy developing to these respective foods.8
Interestingly, what Lack did not envisage, was the concept of
moving from restoring an actively impaired skin barrier, to
attempting to prevent the skin barrier becoming impaired in the
first place. The Barrier Enhancement for Eczema Prevention
(BEEP) study9 investigated the hypothesis that intensive moistu-
rization from birth would prevent the development of eczema
(synonyms: atopic eczema or AD)10 by enhancing the skin bar-
rier. The BEEP trial recruited newborn infants (n 5 1394) from
high-risk families.9 In the intervention arm, families applied a
daily emollient (Diprobase cream or DoubleBase gel at parental
choice) in the first year of life, plus standard skin care advice,
compared with standard skin care advice in the control arm
only. The primary outcome was eczema at age 2 years, diagnosed
using the UK working party criteria.11 The study showed that the
moisturization intervention did not prevent eczema.12 At age 2
years, eczema was present in 139 of 598 infants (23%) in the
emollient group and 150 of 612 infants (25%) in the control group
(adjusted relative risk, 0$95; 95%CI, 0.78-1.16; P5 .61) and was
consistent for other definitions of eczema. In addition, there was a
nonsignificant increase in food sensitization and food allergy at 2
years of age in the intervention arm. Confirmed food allergy to
milk, egg, or peanut occurred in 7.5% (41 of 547) of the emollient
group and 5.1% (29 of 568) of the control group (adjusted odds
ratio [OR], 1.47; 95% CI, 0.93-2.33). Sensitization to 1 or more
of these foods occurred in 11.9% (58 of 487) of the emollient
group and 8.8% (44 of 498) of the control group (adjusted OR,
1.36; 95% CI, 0.94-1.95).
An earlier randomized controlled trial of the application of an
emulsion-typemoisturizer daily during the first 32weeks of life to
59 of 118 Japanese infants at high risk for AD found a reduction in
the development of eczema (19 infants in the intervention group
vs 28 infants in the control group) and the intervention group
maintained intact skin for a significantly longer period than the
control group did (P 5 .012, log-rank test). Whereas the study
reported no statistically significant differences in egg white or
ovomucoid sensitization between the 2 groups at 32 weeks of
age, ovomucoid sensitization was higher in the intervention
group: >_0.35 kU/L threshold: 19% (9 of 48) in intervention group
versus 6.8% (3 of 44) in the control group.13
The Enquiring About Tolerance (EAT) study
(ISRCTN14254740) is the largest published randomized
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consists of a cohort of 1303 infants, meticulously phenotyped
through the first 3 years of life, which also recorded early life
moisturization frequency. The EAT cohort provides an opportu-
nity to further assess the relationship between early moisturiza-
tion and the development of food sensitization and food allergy. In
line with the dual allergen hypothesis, we postulated that frequent
contact of a parent’s hands with their child’s skin during
moisturizer application might be facilitating the transcutaneous
exposure to food allergen, resulting in food allergy developing.METHODS
Participants
A total of 1303 3-month old infants were recruited from the general
population in England and Wales between November 2, 2009, and July 30,
2012. Ethical approval was provided by St Thomas’ Hospital Research Ethics
Committee and informed consent was obtained from the parents of children
enrolled in the study. TheConsolidated Standards of Reporting Trials flowchart
for the primary outcome of the EAT study is shown in Fig E1 in this article’s
Online Repository (available at www.jacionline.org). The original trial proto-
col, final protocol, summary of changes to EAT protocol, original statistical
analysis plan (SAP), final SAP, and summary of changes to SAP have been pub-
lished elsewhere.14,15 All infants were healthy, exclusively breastfed, and born
at term (>_37 weeks’ gestation).
In brief, participants were randomized by simple randomization to the
standard introduction group (SIG) or early introduction group (EIG). The SIG
was asked to exclusively breastfeed to around 6 months of age. Allergenic
food introduction beyond this point was at parental discretion. EIG infants
continued to breastfeed while sequentially introducing 6 allergenic foods:
cow’s milk yogurt, then peanut, hard-boiled egg, sesame, and whitefish (cod)
in a random order, and finally wheat. By week 6, EIG infants were ideally
consuming the required amount of all 6 allergenic foods each week.Procedures
Clinic visits took place at enrollment and at 1 and 3 years of age at which all
children were examined for visible eczema using the UK diagnostic criteria–
based photographic protocol of the International Study of Asthma and
Allergies in Childhood (ISAAC) phase 2.16 Disease severity was determined
by the Scoring Atopic Dermatitis (SCORAD) index.17
Transepidermal water loss (TEWL) was measured with the Biox AquaFlux
AF200 closed condenser chamber device (Biox Systems, London, UK) on
unaffected skin of the volar aspect of the forearm at 3 and 12 months of age.18
Venous blood samples were screened for the 6 commonest filaggrin mutations
in the UK white population.
The enrollment questionnaire enquired about family member’s history of
atopic disorders (asthma, eczema, hay fever, and food allergy). It included a
detailed section on skin problems and treatments. The latter included a
question about current moisturization frequency with the following response
categories: never, once a week or less, 2 to 4 times per week, 5 to 6 times a
week, daily, or more than daily. The name of the moisturizer was asked and the
infant’s age when usage had commenced.
All children who had a positive skin prick test to 1 or more of the 6
intervention foods at the 1-year and/or 3-year assessments, or a history of a
positive challenge at <1 year of age were considered for a food challenge. The
decision to challenge, the timing of challenge, and the type of challenge
undertaken were based on the participant’s study group and frequency of
consumption status.15 In the EAT study, the primary outcome was allergy,
proven by double-blind challenge where possible, to 1 or more of the 6 early
introduction foods.
Skin prick testing was performed at 12 months and 36 months of age to the
6 foods and the aeroallergens house dust mite, cat, dog, grass, and tree pollen
(Stallergenes, Didcot, UK).Statistical analyses
Nonparametric tests for trend with categorical moisturization frequency
were undertaken using the nptrend command in Stata 15 (StataCorp, College
Station, Tex). Among infants with no visible eczema at enrollment, a sensi-
tivity analysis was done to minimize reverse causation, first, by additionally
excluding those with a parent-reported history of the infant ever having had
eczema and, second, by additionally excluding those with a parent-reported
history of the infant ever having had eczema or having a parent-reported his-
tory of dry skin. Univariable and multivariable logistic models were generated
with the outcome being food allergy and with moisturization frequency
included as a categorical variable in one model and as a continuous variable
in another. Variables included in the adjusted models were study group, sex,
number of siblings, number of family members with a history of self-
reported eczema, ethnicity, eczema severity (SCORAD), filaggrin mutation
status, and TEWL. The EAT dataset (ITN900AD) is available through Trial-
Share (www.itntrialshare.org).RESULTS
Of the 1303 participants in the EAT study, 1302were assessed at
the enrollment visit at age 3 months for visible eczema, which was
present in 24.4% (317 of 1302) and absent in 75.6% (985 of 1302).Moisturization usage
Of the 985 infants with no visible eczema, 924 had data on
moisturization frequency at 3 months and 654 (71%) were being
moisturized at least once a week (Table I). Increasing frequency
of moisturization was associated with parents reporting their
infant having generally dry skin or eczema (despite the absence
of visible eczema at the 3-month visit). Excluding infants with
a parent-reported history of eczema (n 5 5) or parent-reported
generally dry skin (n 5 174) or both (n 5 33) left a group of
712 infants who phenotypically appeared to have healthy skin.
Among this group, moisturization rates were still very high,
with 66% (469 of 712) being moisturized at least once a week
and 16% being moisturized once daily or more.
Those moisturized more frequently had higher filaggrin muta-
tion rates (test for trend, P 5 .06). Moisturization frequency was
not associated with the number of first-degree family members
with self-reported eczema except in the moisturized more
frequently than daily group or the median age when moisturizers
had first been applied to the infants’ skin (Table I). Corticosteroid
cream usage was minimal in the infants with no visible eczema at
3 months of age (overall 3.4%, 31 of 924), and among those who
were using it, this was frequently for cradle cap or nappy rash, or
as compound preparations including an antifungal agent, presum-
ably for an area of dermatitis of unknown etiology.
Increasing moisturization frequency in infants with visible
eczema at 3 months was associated with their eczema severity
(SCORAD index). For those with visible eczema at enrollment
but never moisturized, the median SCORAD was 7; those
moisturized daily, 10.8 (P 5 .03 vs never moisturized group);
and those moisturized more frequently than daily, 13.9
(P < .001 versus never moisturized group) (Table I). Corticoste-
roid cream usage was infrequent in infants with visible eczema
(11.7%, 35 of 300), with the exception of infants who were mois-
turized more than daily (35.3%, 19 of 57).
Increasing moisturization frequency at 3 months of age was
also associated with higher concurrent TEWL, in infants with and
without enrollment eczema, as well as in all enrollment infants
combined (Fig 1, right panels).
TABLE I. Moisturization frequency at 3 months and atopy, skin medication usage, and skin barrier characteristics, by visible
eczema status at the enrollment (3 month) visit
Never % (n) 1/wk % (n) 2-4/wk % (n) 5-6/wk % (n) Daily % (n) >Daily % (n) Test for trend
No visible eczema at 3 months (n 5 924) 29.2 (270) 24.9 (230) 19.4 (179) 4.6 (42) 18.2 (168) 3.8 (35) —
Parent-reported generally dry skin 9.6 (26) 16.1 (37) 22.9 (41) 31.0 (13) 39.3 (66) 68.6 (24) <.001
Parent-reported eczema 1.9 (5) 1.7 (4) 2.8 (5) 0 (0) 7.7 (13) 31.4 (11) <.001
Filaggrin mutation* 6.7 (16) 7.9 (17) 7.3 (12) 11.9 (5) 9.6 (15) 18.8 (6) .06
Family members with history of eczema,
n (P value versus Never group)
0.71 0.79 (.27) 0.79 (.27) 0.64 (.62) 0.85 (.07) 1.17 (.001)
Age first moisturized (wk), median
(P value versus 1/week group)
— 3 3 (.55) 4 (.73) 2 (.38) 2 (.82)
Steroid cream use at 3 mo 1.1 (3) 4.4 (10) 3.4 (6) 0 (0) 4.8 (8) 11.4 (4) .01
Visible eczema at 3 mo (n 5 300) 10.3 (31) 13.3 (40) 20.3 (61) 8.3 (25) 28.7 (86) 19.0 (57)
SCORAD at 3 mo, median
(P value versus Never group)
7 7 (.83) 7.2 (.58) 9.1 (.16) 10.8 (.03) 13.9 (<.001)
Filaggrin mutation* 25.0 (7) 22.9 (8) 15.0 (9) 32.0 (8) 30.4 (24) 18.2 (10) .74
Family members with history of eczema, n
(P value versus Never group)
1.23 0.85 (.09) 1.03 (.35) 1.08 (.54) 1.16 (.75) 1.02 (.31)
Age first moisturized (wk), median
(P value versus 1/week group)
— 4 4 (.62) 1 (.06) 5 (.35) 4 (.69)
Steroid cream use at 3 mo 6.5 (2) 2.5 (1) 3.3 (2) 12.0 (3) 9.3 (8) 33.3 (19) <.001
*Filaggrin mutation data on 848 (no visible eczema) and 282 (visible eczema) participants.
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The 20 most frequently used moisturizers at the 3-month visit
are listed in Table II. Among those without eczema, olive oil pre-
dominated, but multiple other food-derived oils also feature in the
list: sunflower, almond, coconut, and vegetable oil. Olive oil was
also the most frequently used moisturizer in infants with visible
eczema, followed by various prescribed moisturizing creams.Bathing frequency
Bathing frequency and moisturization frequency at 3 months
were strongly correlated (P < .0005), suggesting that the 2 activ-
ities occurred in conjunction for most infants. We have previously
shown that bathing frequency at 3 months had a statistically sig-
nificant independent dose-response relationship with TEWL at 3
months and 1 year and a relationship with visible eczema at 3
months.19 However, the relationship with TEWL for bathing fre-
quency (change in TEWL per unit increase in weekly bathing fre-
quency: 0.42 g/m2h; 95% CI, 0.24-0.61; P < .0005), was weaker
than for moisturization frequency (change in TEWL per unit in-
crease in weekly moisturization frequency: 0.63 g/m2h; 95%
CI, 0.53-0.73; P < .0005).Primary outcome: Food allergy
In the 1161 EAT participants evaluable for the primary
outcome (89.1% of the 1303 enrolled participants), 74 cases of
food allergy developed: 48 in the 284 infants with visible eczema
at enrollment (16.9%), and 26 in the 877 infants without visible
eczema at enrollment (3.0%). In univariate analysis, a significant
dose-response relationship was observed between moisturization
frequency and the development of food allergy in infants without
visible eczema at enrollment (Fig 1, A) , in infants with visible
eczema at enrollment (Fig 1, B), and in all infants combined
(Fig 1, C) (for all, P < .0005).
Crude and adjusted logistic models were undertaken with
moisturization frequency as a categorical variable (Fig 2, leftpanels), and as a continuous variable (Fig 2, right panels).
Despite adjustment for relevant potential confounding vari-
ables, the dose-response relationship remained, whether the
analysis was undertaken in infants with no visible eczema at
enrollment (Fig 2, A), in those with visible eczema at
enrollment (Fig 2, B), or in all infants (Fig 2, C). When
moisturization frequency was treated as a continuous variable,
each additional moisturization per week was associated with an
18% increase in the odds of developing food allergy (adjusted
OR [ORadj], 1.18; 95% CI, 1.07-1.30; P5 .001) for infants with
no visible eczema at enrollment; 20% for infants with visible
eczema (ORadj, 1.20; 95% CI, 1.11-1.31; P < .0005); and 20%
for all enrollment infants (ORadj, 1.20; 95% CI, 1.13-1.27;
P < .0005). In contrast, there was no relationship between
3-month bathing frequency and the development of food
allergy in the cohort overall (ORadj, 0.95; 95% CI, 0.83-1.08;
P 5 .41) or within those with (ORadj, 1.00; 95% CI,
0.84-1.18; P 5 .98) or without (ORadj, 0.89; 95% CI,
0.73-1.08; P 5 .25) visible eczema at 3 months of age.
An additional analysis was undertaken to assess whether the
type of moisturizer (oil- or cream-based) affected the results, but
there was insufficient power to identify any formulation-specific
effect.Enrollment (3-month) sensitization
At enrollment onto the EAT study at 3 months of age, infants in
the EIG underwent skin prick testing to the 6 early introduction
foods: 33 of 652 EIG infants (5.1%) were positive (any wheal
size). Blood sampling for specific IgE testing was attempted in all
infants in both the EIG and the SIG at enrollment. A positive
specific IgE to 1 or more foods (IgE >_0.35 kU/L) at 3 months was
present in 74 of 1170 infants (6.3%) in whom it was possible to
obtain blood. We have previously shown that enrollment sensi-
tization at 3 months based on skin prick testing in the EIG20 or on
specific IgE testing in the SIG21 (and hence independent of the



























Never 1/week 2-4/week 5-6/week Daily >Daily
Moisturization frequency
Change in TEWL per unit increase in moisturization frequency: 0.26 g/m2*h (0.18-0.34), p<0.0005
(left panel n=828, right panel n=921)
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Moisturization frequency
Change in TEWL per unit increase in moisturization frequency: 0.78 g/m2*h (0.51-1.05), p<0.0005
(left panel n=270, right panel n=300)
































Never 1/week 2-4/week 5-6/week Daily >Daily
Moisturization frequency
Change in TEWL per unit increase in moisturization frequency: 0.63 g/m2*h (0.53-0.73), p<0.0005
(left panel n=1,098, right panel n=1,221)




FIG 1. Moisturization frequency at 3 months and food allergy (left panels) and 3 months TEWL (right
panels), by visible eczema status at the 3-month visit: no visible eczema (A), visible eczema (B), and all par-
ticipants (C). Note change of scale of axes between panels. Left-hand panels include participants with (i)
visible eczema status at enrollment determined, (ii) enrollment general questionnaire completed including
the moisturization frequency question, and (iii) their primary outcome status determined. Right-hand
panels include participants with (i) and (ii) as described for the left-hand panels and (iii) TEWLmeasurement
undertaken at enrollment.
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3 months was associated with the early emergence of food
sensitization: in the EIG, ORadj for being skin prick
test–positive at 3 months of age to any of the EAT study early
introduction foods, for each unit increase in weeklymoisturization frequency, was 1.10 (95% CI, 1.01-1.20;
P 5 .04); and in the total study population, ORadj for being spe-
cific IgE positive at 3months of age to any of the EAT study foods,
for each unit increase in weekly moisturization frequency, was
1.11 (95% CI, 1.03-1.18; P 5 .003).
TABLE II. Top 20 products most frequently used as moisturizers on infants with and without visible eczema at the 3-month visit
No visible eczema at 3 mo Visible eczema at 3 mo
Moisturizer Frequency % (Cumulative %) Moisturizer Frequency % (Cumulative %)
1 Olive oil 151 23.1 (23.1) 1 Olive oil 49 18.2 (18.2)
2 Johnson’s baby oil 74 11.3 (34.5) 2 Diprobase 27 10.0 (28.3)
3 E45 39 6.0 (40.4) 3 Doublebase 22 8.2 (36.4)
4 Johnson’s baby lotion 36 5.5 (45.9) 4 Aqueous cream 18 6.7 (43.1)
5 Oilatum 29 4.4 (50.4) 5 Oilatum 15 5.6 (48.7)
6 Aqueous cream 27 4.1 (54.5) 6 Aveeno 14 5.2 (53.9)
7 Diprobase 18 2.8 (57.3) 7 Epaderm 13 4.8 (58.7)
8 Sunflower oil 16 2.5 (59.7) 8 E45 12 4.5 (63.2)
9 Aveeno 15 2.3 (62.0) 9 Johnson’s baby oil 12 4.5 (67.7)
10 Almond oil 13 2.0 (64.0) 10 Cetraben 11 4.1 (71.8)
11 Epaderm 13 2.0 (66.0) 11 Johnson’s baby lotion 6 2.2 (74.0)
12 Coconut oil 12 1.8 (67.8) 12 Coconut oil 5 1.9 (75.8)
13 DoubleBase 12 1.8 (69.7) 13 Hydromol 5 1.9 (77.7)
14 Sudocrem 12 1.8 (71.5) 14 Sunflower oil 5 1.9 (79.6)
15 Cetraben 9 1.4 (72.9) 15 Dermol 4 1.5 (81.0)
16 Baby oil 8 1.2 (74.1) 16 Emulsifying ointment 3 1.1 (82.2)
17 Neal’s yard baby oil 8 1.2 (75.3) 17 Baby lotion 2 0.7 (82.9)
18 Vegetable oil 8 1.2 (76.6) 18 Boots baby moisturiser 2 0.7 (83.6)
19 Vaseline 6 0.9 (77.5) 19 Boots baby oil 2 0.7 (84.4)
20 Weleda calendula lotion/oil 6 0.9 (78.4) 20 Burt’s bees lotion 2 0.7 (85.1)
None of the items listed were trilipid/ceramide-containing products.
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A sensitivity analysis was undertaken to mitigate the
possibility that in those infants with no visible eczema at
enrollment, reverse causality might be affecting the relationship
between moisturization frequency and the emergence of food
allergy. The odds of developing food allergy for each additional
moisturization per week remained significant both in infants
with no visible eczema at enrollment and no parent-reported
eczema (ORadj, 1.16; 95% CI, 1.03-1.30; P 5 .01) and in in-
fants with no visible eczema at enrollment and no parent-
reported eczema or generally dry skin (ORadj, 1.16; 95% CI,
1.01-1.33; P 5 .04).
Of the 1303 infants enrolled onto the EAT study at 3 months of
age, 1129 (87%) had at least 1 first-degree relative (mother, father,
or sibling) with parent-reported eczema, hay fever, or asthma. Of
the 74 cases of food allergy that occurred in the EAT study, 73
were within this high-risk group. Repeating the analyses under-
taken in this paper, but restricted to this high-risk group,
analogous to the BEEP study participants, yielded very similar
results (data not shown).Food and aeroallergen sensitization
With regard to the development of food and aeroallergen
sensitization, as assessed by skin prick testing at the 36-month
clinical visit, statistically significant dose-response relationships
were seen between increasing moisturization frequency and
sensitization rates in infants without visible eczema (Fig 3, A),
in those with visible eczema (Fig 3, B), and in all infants (Fig 3,
C). Particularly for the latter, a dose-response relationship with
both food and aeroallergen sensitization was notable (both rela-
tionships, P < .0005).Eczema development
There was no evidence that increased moisturization frequency
at enrollment in infants with no history of eczema or generallydry skin or visible eczema at the 3-month visit, protected against
the development of eczema at the 12-month or 36-month visit
(Fig 4).DISCUSSION
In this analysis of a well-phenotyped cohort of infants
participating in the EAT study, we confirm a positive association
between early moisturization and the development of food
allergy and sensitization, with a dose-dependent relationship
with moisturization frequency. This relationship was present both
in infants with and without eczema at the enrollment visit.
That such a relationship was present among infants with
eczemamight simply be attributed to a dose-response relationship
between severity of eczema, known to be strongly associated with
food allergy, and frequency of moisturization. However, the
analysis adjusted for eczema severity, as well as filaggrin muta-
tion status. Most compelling is that the relationship was present
even in infants without visible eczema. This too might be refuted
on the grounds that eczema is a waxing and waning condition and
that some of these infants might have already had eczema without
it being present at the 3-month enrollment visit or have had a
propensity to dry skin that would ultimately evolve into overt
eczema. However, the dose-response relationship persisted even
when infants whose parents reported a history of eczema or a
history of dry skin were excluded.
Two-thirds of EAT study infants with no history of eczema or
dry skin were being actively moisturized, as frequently as daily or
more and a number of respondents mentioned that it was for baby
massage. Moisturization as part of baby skin care is frequently
recommended: in a survey of all UKmaternity and neonatal units,
more than one-half (52.1%) recommended oil for baby skin care.
Of those recommending oil, 81.6% recommended olive oil to
moisturize the skin, whereas 69.4% suggested its use for baby
massage.22 Consistent with these findings, in the EAT study, the
most commonly used product for moisturization was olive oil,
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FIG 2. Moisturization frequency at 3 months and food allergy (crude and adjusted analysis), by visible
eczema status at the 3-month visit: no visible eczema (A), visible eczema (B), and all participants (C). Left-
hand panels show the results for moisturization frequency as a categorical variable, with the never moistur-
ized category as baseline (OR, 1.0). Right-hand panels show the results for moisturization frequency treated
as a continuous variablewith the OR shown being for each unit increase in weeklymoisturization frequency.
Crude (unadjusted) analysis restricted to participants with complete covariate data. Adjusted analysis was
adjusted for study group, sex, number of siblings, number of family members with history of eczema,
ethnicity, eczema severity (SCORAD) (B and C), filaggrin mutation status, and TEWL.
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visit.
There are 2 possible explanations for our findings: moistur-
izers might be facilitating the passage of food allergens acrossthe skin barrier, or moisturizers might be damaging the skin
barrier and allowing the passage of the food allergen. Mois-
turizers are known to facilitate the passage of substances across














































Never 1/week 2-4/week 5-6/week Daily >Daily
Moisturization frequency
p=0.02
(left panel n=845, right panel n=806)


















































Never 1/week 2-4/week 5-6/week Daily >Daily
Moisturization frequency
p<0.0005
(left panel n=277, right panel n=264)














































Never 1/week 2-4/week 5-6/week Daily >Daily
Moisturization frequency
p<0.0005
(left panel n=1,122, right panel n=1,070)




FIG 3. Moisturization frequency at 3 months and food (left panels) and aeroallergen (right panels)
sensitization at 36 months, by visible eczema status at the 3-month visit: no visible eczema (A), visible
eczema (B), and all participants (C). Note change of scale of axes between panels.
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2,4-dichlorophenoxyacetic acid, with the more effective mois-
turizers having a greater effect on 2,4-dichlorophenoxyacetic
acid absorption.23 Thus transfer of allergenic proteins from the
parent’s hands to their infant could be occurring when they are
applying moisturizer to their infant’s skin. With regard to the
second explanation, previous research has shown that olive
oil (and other vegetable oils) may impede the development ofthe lamellar lipid structures of the permeability barrier from
birth. The investigators concluded that it was difficult to sup-
port the use of sunflower or olive oils on babies’ skin.24 The
detergent, sodium lauryl sulfate, historically a common ingre-
dient in soaps, shampoos, and other skin care products, has
also been shown to disrupt the skin barrier.25 Hence the
dose-response relationship observed between increasing mois-
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FIG 4. Moisturization frequency at 3months and the development of visible eczema at 12months (A) and 36
months (B), among infants with no visible eczema at the 3-month visit. Note change of scale of axes
between panels.
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fect of the moisturizer on the skin barrier. The 2 explanations
are not mutually exclusive, and it may be that a combination
of both explanations is responsible for our findings.
The next-generation trilipid skin barrier creams, containing
ceramides, cholesterol, and free fatty acids, which aim to mimic
the skin’s natural pH and lipid composition, may not influence
food sensitization development in the same way. A recent small
pilot randomized controlled study comparing 12 weeks of daily
application of a triplipid cream (EpiCeram; Primus Pharmaceu-
ticals, Scottsdale, Ariz) versus a paraffin-/petrolatum-based
cream (Aveeno; Johnson & Johnson, New Brunswick, NJ) found
that the triplid cream decreased total IgE and increased total IgG4,
as well as increasing total and peanut-specific IgG4/IgE ratios.
26
Furthermore, a separate small study found that EpiCeram reduced
TEWL much more markedly than Aveeno did.27
The association between moisturization and food allergy
development in infants with no visible eczema is consistent
with our previous observation in the EAT cohort that skin barrier
impairment can be present in the absence of clinical eczema:
TEWL measured at 3 months was elevated in filaggrin mutation
carriers unaffected by eczema.28
The route of exposure that is most relevant for the development
of sensitization to aeroallergens is not known.29 However, epicu-
taneous house dust mite application in a murine model has been
shown to result in house dust mite sensitization developing.30Strengths and limitations
The primary outcome in the EAT study, food allergy, was
robustly diagnosed. In the EAT study, of the 74 participants who
developed a food allergy, 70 were diagnosed based on double-
blind, placebo-controlled food challenges (and 4 on a history of a
skin prick test reaction of 5 mm or more). Eczema diagnoses were
made using validated tools and infants had measures of skin
barrier function performed (TEWL) and their filaggrin mutation
status evaluated. The principal limitation is that we lack any
mechanistic data to explain the finding.Conclusions
The observation has been made that the increased availability
and use of baby skin care products has coincided with the
increased prevalence of eczema.24 Given the strong link between
the development of eczema and food allergy, this raises the pos-
sibility that the use of such products might have contributed to
the levels of food allergy that are currently seen. Taken together,
our findings and those of prior studies suggest that emollients may
facilitate transcutaneous sensitization to both food and aeroaller-
gens. These findings are potentially of great significance, and
further research is required to understand the mechanism of ac-
tion. To be determined are whether moisturizers facilitate food
and aeroallergen uptake; whether moisturizers become contami-
nated by these allergens from the hands or the environment; and
whether the effects are limited to certain types of moisturizer or
to specific susceptible individuals. It is important that planned
and future studies of moisturizer use in infancy aimed at
preventing eczema also measure food allergy outcomes that can
be combined with other studies in an ongoing individual patient
meta-analysis.31 In the interim it would seem sensible that before
moisturizers are applied, hands are washed thoroughly,
and that careful consideration be given to the frequency of
moisturizer application and the type of moisturizer used in infant
skin care.
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Clinical implications: Frequent skin moisturization in early life
might promote the development of food allergy, most likely
through transcutaneous sensitization.REFERENCES
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1319 Parcipants were screened for EAT study
16 ineligible for enrollment: major health 
concerns idenfied from blood test 
results/clinical findingsa
1303 Randomized
652 Were assigned to the EIG651 Were assigned to the SIG
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595 Were included
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56 Had missing data on outcomes
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of diagnosc algorithm
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SIG Adherence nonevaluable








SIG Non per protocol
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FIG E1. EAT enrollment and randomization. Baseline visits occurred when participants were 3 months of
age. The primary outcome for the EAT study was challenge-proven food allergy to 1 or more of the 6 early
introduction foods between 1 and 3 years of age. aEight infants randomized to each group were found to
have significant health issues either on blood testing or the clinical examination at the enrollment visit,
rendering them ineligible for enrollment: conditions included severe vitamin D deficiency, severe iron defi-
ciency, severe failure to thrive, familial hypercholesterolemia, congenital stridor, epidermolysis bullosa,
and cartilage hair hypoplasia syndrome. bForty-three participants in the SIG and 69 participants in the
EIG withdrew voluntarily from the study. Reasons given were as follows: concerns about the blood tests
(SIG 0, EIG 2), emigration (SIG 10, EIG 12), expenses (SIG 1, EIG 1), family health issues (SIG 3, EIG 0), family
issues (SIG 2, EIG 4), no reason given (SIG 11, EIG 16), lost contact with family (SIG 15, EIG 28), too far to
travel for study assessments (SIG 0, EIG 1), and unhappy participating in the study (SIG 1, EIG 5).
ITT, intention-to-treat.
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